Skip to content
MarketScale
‹ Back to IndustriesSciences

TMC Vibration Control Contributes To Groundbreaking Cancer Research

TMC Vibration Control has partnered with the Oregon Health and Science University (OHSU) to help stabilize the advanced microscopes OHSU researchers use to study the nanobiology of cancer. TMC’s technology is essential for high-resolution imaging and accurate scientific research. Vibrations in the environment, such as from traffic, can cause the imaging equipment to shake,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · CancerClaudia S. LopezDr. Joe W. GrayJessica Riesterer
Share

Key takeaways

01

TMC Vibration Control has partnered with the Oregon Health and Science University (OHSU) to help stabilize the advanced microscopes OHSU researchers use to study the nanobiology of cancer.

02

TMC’s technology is essential for high-resolution imaging and accurate scientific research.

03

Vibrations in the environment, such as from traffic, can cause the imaging equipment to shake,…

TMC Vibration Control has partnered with the Oregon Health and Science University (OHSU) to help stabilize the advanced microscopes OHSU researchers use to study the nanobiology of cancer.

TMC’s technology is essential for high-resolution imaging and accurate scientific research. Vibrations in the environment, such as from traffic, can cause the imaging equipment to shake, which can lead to blurred or distorted images.

The ability to study cells and tissues at the nanoscale level is essential for understanding how they function and how diseases like cancer progress. Understanding these diseases could save millions of lives. In 2023, about 1.9 million new cancer cases are expected to be diagnosed in the U.S. alone. According to the World Health Organization, cancer is a leading cause of death around the world.

TMC Vibration Control is crucial in enabling researchers, like those at OHSU, to develop a deeper understanding of the molecular and cellular mechanisms of disease, ultimately leading to improved diagnosis, treatment, and prevention of diseases.

Some of the researchers at OHSU, including Claudia S. Lopez, Ph.D., Jessica Riesterer, Ph.D. and Dr. Joe W. Gray, Ph.D., and Mike Georgalis, the North American Sales Manager for TMC, explain more about how OHSU and TMC work together to enable the groundbreaking research needed to cure cancer.

Claudia, Jessica, Joe and Mike’s Thoughts:

Claudia: OHSU is Oregon Health and Science University. It’s an academic institution and also a big hospital that serves the Oregon community. At the same time, it has a big research component in the basic science and also in the translational field. Both the local OHSU multiscale Microscopy Core and the Pacific Northwest Cryo-EM Center share the same facility in the basement of the Robertson Life Science Building at OHSU. Access to those facilities is different. While the local facility is a fee for service, the NIH Center is at no cost for those, all of those users having approved projects.

Jessica: As a staff scientist, I assist a lot of the projects as part of the Knight Cancer Institute in looking at the nanobiology of cancer. There’s a big push to look at how cancer cells are organized with their architecture at the cellular level, and so we need the highest resolution in order to do that.

Joe: One of the opportunities with the technologies that we have is to be able to see with few nanometer resolution the features that make up these cells and tissues. The challenge here, of course, is to make these measurements using technologies that run over periods of days to generate the dataset.

Claudia: Having all these microscopes in a good environment is essential. These instruments are very sensitive to vibration, to noise, and to electromagnetic interference.

Jessica: Environmental noise has affected our data, especially in this building. We are surrounded by the light rail, the river, the streetcar. That all affects our imaging.

Claudia: All of our electron microscopes are installed over TMC tables, and that has proven to be essential to be able to operate these instruments at their highest performance possible.

Mike: OHSU deployed the Stasis Active Piezoelectric Cancellation System, which contains sensors inside, which monitor the state of the system, and through active feedback control, they operate piezoelectric actuators, which expand and contract, essentially equally and opposite to the vibration that’s sensed.

Claudia: TMC has helped us mitigate all the vibrations that we have in this facility. On the TMC tables, we are at zero vibrations, which is essential for especially the high-end instruments that we have in the facility.

Jessica: TMC’s vibration control has allowed us to image at the highest resolution, including the nanoscale, and without that, we’d have skewed data.

Joe: We have finally gotten to the point in measurement science that we are able to define the components in the organizations of cells and tissues, and I think it’s going to give us a lot of insight as to how the components work together to actually produce the functions that we observe in the cells and tissues that we look at in the light microscope. So it’s an exciting time, lots to learn, a lot of challenges in terms of interpreting the data, but the measurement tools are there, and I think it’s going to be fun to watch how the field evolves.

Jessica: Cancer affects everyone. Everyone knows someone who’s had it or has it, and to be able to stop that for both the patient and for their loved ones would be life-changing.

Mike: What makes me proud about being at TMC and partnering with organizations like OHSU is that we get to be a small part of the groundbreaking research that’s being performed by Claudia and her colleagues that really has the potential to make an impact on a larger scale.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512